» Articles » PMID: 33909518

Common Themes in Early State Policy Responses to Substance Use Disorder Treatment During COVID-19

Overview
Publisher Informa Healthcare
Specialty Psychiatry
Date 2021 Apr 28
PMID 33909518
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

: Limited research has examined how states have changed policies for treatment of substance use disorder (SUD) during the COVID-19 pandemic.: We aimed to identify themes in state policy responses to the pandemic in the context of SUD treatment. Identifying themes in policy responses provides a framework for subsequent evaluations of the relationship between state policies and health service utilization.: Between May and June 2020, we searched all Single State Agencies for Substance Abuse Services (SSA) websites for statements of SUD treatment policy responses to the pandemic. We conducted Iterative Categorization of policies for outpatient programs, opioid treatment programs, and other treatment settings to identify themes in policy responses.: We collected 220 documents from SSA websites from 45 states and Washington D.C. Eight specific themes emerged from our content analysis: delivery of pharmacological and non-pharmacological services, obtaining informed consent and documentation for remote services, conducting health assessments, facility operating procedures and staffing requirements, and permissible telehealth technology and billing protocols. Policy changes often mirrored federal guidance, for instance, by expanding methadone take-home options for opioid treatment programs. The extent and nature of policy changes varied across jurisdictions, including telehealth technology requirements and staffing flexibility.: States have made significant policy changes to SUD treatment policies during COVID-19, particularly regarding telehealth and facilitation of remote care. Understanding these changes could help policymakers prioritize guidance during the pandemic and for future health crises. Impacts of policies on disparate treatment populations, including those with limited technological access, should be considered.

Citing Articles

Patient Engagement in Providing Telehealth SUD IOP Treatment: A Retrospective Cohort Study.

Contreras-Schwartz J, ONeill C, Threlkeld A, OCallaghan E, Winsberg M Healthcare (Basel). 2025; 12(24.

PMID: 39765981 PMC: 11675410. DOI: 10.3390/healthcare12242554.


Nurse Care Management of Opioid Use Disorder Treatment After 3 Years: A Secondary Analysis of the PROUD Cluster Randomized Clinical Trial.

Lapham G, Hyun N, Bobb J, Wartko P, Matthews A, Yu O JAMA Netw Open. 2024; 7(11):e2447447.

PMID: 39576637 PMC: 11584924. DOI: 10.1001/jamanetworkopen.2024.47447.


Associations Between State Policies Facilitating Telehealth and Buprenorphine Episode Initiation and Duration Early in the COVID Pandemic : State Telehealth Policies and Buprenorphine.

Stein B, Saloner B, Sheng F, Sorbero M, Dick A, Gordon A J Gen Intern Med. 2024; .

PMID: 39543071 DOI: 10.1007/s11606-024-09188-6.


Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff.

Mitchell S, Jester J, Gryczynski J, Whitter M, Fuller D, Halsted C Addict Sci Clin Pract. 2023; 18(1):61.

PMID: 37848970 PMC: 10580566. DOI: 10.1186/s13722-023-00417-7.


How are state telehealth policies associated with services offered by substance use disorder treatment facilities? Evidence from 2019 to 2022.

Agniel D, Cantor J, Golan O, Yu H, Andraka-Christou B, Simon K Drug Alcohol Depend. 2023; 252:110959.

PMID: 37734281 PMC: 10731590. DOI: 10.1016/j.drugalcdep.2023.110959.


References
1.
Wang Q, Kaelber D, Xu R, Volkow N . COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2020; 26(1):30-39. PMC: 7488216. DOI: 10.1038/s41380-020-00880-7. View

2.
Khatri U, Pizzicato L, Viner K, Bobyock E, Sun M, Meisel Z . Racial/Ethnic Disparities in Unintentional Fatal and Nonfatal Emergency Medical Services-Attended Opioid Overdoses During the COVID-19 Pandemic in Philadelphia. JAMA Netw Open. 2021; 4(1):e2034878. PMC: 7821023. DOI: 10.1001/jamanetworkopen.2020.34878. View

3.
Nunes E, Levin F, Reilly M, El-Bassel N . Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?. J Subst Abuse Treat. 2020; 122:108196. PMC: 7666540. DOI: 10.1016/j.jsat.2020.108196. View

4.
Volkow N . Collision of the COVID-19 and Addiction Epidemics. Ann Intern Med. 2020; 173(1):61-62. PMC: 7138334. DOI: 10.7326/M20-1212. View

5.
Burris S, Ashe M, Levin D, Penn M, Larkin M . A Transdisciplinary Approach to Public Health Law: The Emerging Practice of Legal Epidemiology. Annu Rev Public Health. 2015; 37:135-48. PMC: 5703193. DOI: 10.1146/annurev-publhealth-032315-021841. View